Dexrazoxane
NDC Package 55390-014-02
Package Information
Dexrazoxane is used to reduce the risk and severity of heart damage caused by doxorubicin treatment and similar cancer chemotherapy medications. Marketed by Bedford Laboratories, this product is identified by NDC 55390-014 and is authorized under FDA application ANDA076068.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 55390 - Bedford Laboratories
- 55390-014 - Dexrazoxane
- 55390-014-02 - 1 KIT in 1 PACKAGE * 25 mL in 1 VIAL * 25 mL in 1 VIAL (55390-015-01)
- 55390-014 - Dexrazoxane
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 55390-014-02 identifies a specific commercial package of 1 kit in 1 package * 25 ml in 1 vial * 25 ml in 1 vial (55390-015-01) of Dexrazoxane, labeled by Bedford Laboratories. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Bedford Laboratories on March 31, 2005. The current certification is valid through May 31, 2012.
What are the primary indications for this medication?
Dexrazoxane is used to reduce the risk and severity of heart damage caused by doxorubicin treatment and similar cancer chemotherapy medications. Heart damage limits the length of time you can be treated with doxorubicin. Dexrazoxane allows you to continue doxorubicin treatment for longer. When used for this purpose, dexrazoxane treatment is usually started after you have received several doses of doxorubicin. It is usually not given with the first doses of doxorubicin since doing so may reduce the effectiveness of doxorubicin.
How is this Bedford Laboratories product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 55390001402. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.